Aspirin and other nonsteroidal anti-inflammatory drugs and risk of non-hodgkin lymphoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 3, 2013, Pages 422-428

  Teras, Lauren R ^a   Gapstur, Susan M ^a   Patel, Alpa V ^a   Thun, Michael J ^a   Diver, W Ryan ^a   Zhai, Yusheng ^a   Jacobs, Eric J ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; FOLLOW-UP STUDIES; GEORGIA; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 84876525978     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1158     Document Type: Article

References (25)

1. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
2. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12.
3. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
4. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results froma case-control study in Los Angeles County. Cancer Res 1992;52: 5510s-5s.
5. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 2003;106:784-8. (Pubitemid 36993403)
6. Kato I, Koenig KL, Shore RE, Baptiste MS, Lillquist PP, Frizzera G, et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 2002;13:965-74. (Pubitemid 36169480)
7. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase- 2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer 2011;105:452-9.
8. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 2003;158:316-27. (Pubitemid 41288799)
9. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28. (Pubitemid 38988028)
10. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB. Regular use of aspirin or acetaminophen and risk of non- Hodgkin lymphoma. Cancer Causes Control 2005;16:301-8. (Pubitemid 40897849)
11. Hoeft B, Becker N, Deeg E, Beckmann L, Nieters A. Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma. Cancer Causes Control 2008;19:163-73.
12. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13:518-27.
13. Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma-metaanalyses of the effects of corticosteroids and non-steroidal antiinflammatories. Rheumatology (Oxford) 2007;46:690-4. (Pubitemid 46523318)
14. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006; 17:871-88. (Pubitemid 44081706)
15. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol 2003; 157:510-6. (Pubitemid 36292909)
16. Flick ED, Chan KA, Bracci PM, Holly EA. Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol 2006;164:497-504. (Pubitemid 44576617)
17. Chang ET, Smedby KE, Hjalgrim H, Schollkopf C, Porwit-MacDonald A, Sundstrom C, et al. Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2005;162:965-74. (Pubitemid 41619467)
18. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5: 138-46. (Pubitemid 24073387)
19. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15. (Pubitemid 47073542)
20. Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 2011;29:2424-31.
21. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:2490-501. (Pubitemid 34457132)
22. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 1993;137:235-41. (Pubitemid 23083676)
23. Turner JJ, Morton LM, LinetMS, Clarke CA, Kadin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90-8.
24. Garfinkel L. Selection, follow-up, and analysis in the American Cancer Society prospective studies. Natl Cancer Inst Monogr 1985;67:49-52. (Pubitemid 15031260)
25. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.